Dendritic Cell-based Vaccines in Breast and Gynaecologic Cancer

Anticancer Research

Volumn 23, Issue 5 B, 2003, Pages 4293-4303

  Hernando, Juan José ^a   Park, Tjoung Won ^a   Kuhn, Walther C ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Breast; Cervical cancer; Dendritic cells; Ovarian

Indexed keywords

TUMOR ANTIGEN;

ADVANCED CANCER; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; B CELL LYMPHOMA; BREAST CANCER; CANCER IMMUNOTHERAPY; CELL ACTIVATION; CELL CLONING; CELL PROLIFERATION; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; IMMUNOSTIMULATION; KIDNEY CARCINOMA; MELANOMA; MYELOMA; NONHUMAN; OVARY CANCER; PRIMARY IMMUNE RESPONSE; PRIORITY JOURNAL; PROSTATE CARCINOMA; REVIEW; TUMOR CELL; TUMOR IMMUNITY; UTERINE CERVIX CANCER;

ANIMALS; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CANCER VACCINES; DENDRITIC CELLS; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE;

EID: 0345303849     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (102)

1. Therasse P, Piccart M, van de Velde CJ and Jassem J: The EORTC Breast Cancer Group: 40 years of research contributing to improve breast cancer management. Eur J Cancer 38 Suppl 4: S39-43, 2002.
2. Muderspach LI, Blessing JA, Levenback C and Moore JL Jr: A Phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol 81: 213-215, 2001.
3. Kuhn W, Rutke S, Spathe K, Schmalfeldt B, Florack G, von Hundelshausen B, Pachyn D, Ulm K and Graeff H: Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma. Cancer 92: 2585-2591, 2001.
4. Van den Eynde BJ and van der Bruggen P: T cell defined tumor antigens. Curr Opin Immunol 9: 684-693, 1997.
5. Guermonprez P, Valladeau J, Zitvogel L, Thery C and Amigorena S: Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 20: 621-667, 2002.
6. Russell JH and Ley TJ: Lymphocyte-mediated cytotoxicity. Annu Rev Immunol 20: 323-370, 2002.
7. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B and Palucka K: Immunobiology of dendritic cells. Annu Rev Immunol 18: 767-811, 2000.
8. Gallucci S and Matzinger P: Danger signals: SOS to the immune system. Curr Opin Immunol 13: 114-119, 2001.
9. Thurner B, Roder C, Dieckmann D, Heuer M, Kruse M, Glaser A, Keikavoussi P, Kampgen E, Bender A and Schuler G: Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Methods 223: 1-15, 1999.
10. Pardoll DM: Cancer vaccines. Nat Med 4: 525-531, 1998.
11. Melief CJ, Toes RE, Medema JP, van der Burg SH, Ossendorp F and Offringa R: Strategies for immunotherapy of cancer. Adv Immunol 75: 235-282, 2000.
12. Marincola FM, Jaffee EM, Hicklin DJ and Ferrone S: Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 74: 181-273, 2000.
13. Smyth MJ and Trapani JA: Lymphocyte-mediated immunosurveillance of epithelial cancers? Trends Immunol 22: 409-411, 2001.
14. Walker LS and Abbas AK: The enemy within: keeping self-reactive T cells at bay in the periphery. Nat Rev Immunol 2: 11-19, 2002.
15. Toes RE, van der Voort EI, Schoenberger SP, Drijfhout JW, van Bloois L, Storm G, Kast WM, Offringa R and Melief CJ: Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells. J Immunol 160: 449-4456, 1998.
16. De Bruijn ML, Schuurhuis DH, Vierboom MP, Vermeulen H, de Cock KA, Ooms ME, Ressing ME, Toebes M, Franken KL, Drijfhout JW, Ottenhoff TH, Offringa R and Melief CJ: Immunization with human papillomavirus type 16 (HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV16-induced tumor cells. Cancer Res 58: 724-731, 1998.
17. Steinman RM: The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9: 271-296, 1991.
18. Hart DN: Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 90: 3245-3287, 1997.
19. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF and Heath WR: Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393: 478-480, 1998.
20. Ridge JP, Di Rosa F and Matzinger P: A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 393: 474-478, 1998.
21. Schoenberger SP, Toes RE, van der Voort EI, Offringa R and Melief CJ: T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393: 480-483, 1998.
22. Coughlin CM, Salhany KE, Gee MS, LaTemple DC, Kotenko S, Ma X, Gri G, Wysocka M, Kim JE, Liu L, Liao F, Farber JM, Pestka S, Trinchieri G and Lee WM: Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity 9: 25-34, 1998.
23. Patterson S: Flexibility and cooperation among dendritic cells. Nat Immunol 1: 273-274, 2000.
24. Fernandez NC, Lozier A, Flament C, Ricciardi-Castagnoli P, Bellet D, Suter M, Perricaudet M, Tursz T, Maraskovsky E and Zitvogel L: Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med 5: 405-411, 1999.
25. Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT and Falo LD, Jr: Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med 183: 283-287, 1996.
26. Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D, Ricciardi-Castagnoli P, Raposo G and Amigorena S: Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med 4: 594-600, 1998.
27. Miller PW, Sharma S, Stolina M, Butterfield LH, Luo J, Lin Y, Dohadwala M, Batra RK, Wu L, Economou JS and Dubinett SM: Intratumoral administration of adenoviral interleukin 7 gene-modified dendritic cells augments specific antitumor immunity and achieves tumor eradication. Hum Gene Ther 11: 53-65, 2000.
28. Timmerman JM and Levy R: Dendritic cell vaccines for cancer immunotherapy. Annu Rev Med 50: 507-529, 1999.
29. Fong L and Engleman EG: Dendritic cells in cancer immunotherapy. Annu Rev Immunol 18: 245-273, 2000.
30. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG and Levy R: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2: 52-58, 1996.
31. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G and Schadendorf D: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4: 328-332, 1998.
32. Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A, Taquet S, Coquery S, Wittkowski KM, Bhardwaj N, Pineiro L, Steinman R and Fay J: Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 61: 6451-6458, 2001.
33. Murphy GP, Tjoa BA, Simmons SJ, Ragde H, Rogers M, Elgamal A, Kenny GM, Troychak MJ, Salgaller ML and Boynton AL: Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment. Prostate 39: 54-59, 1999.
34. Fong L, Brockstedt D, Benike C, Wu L and Engleman EG: Dendritic cells injected via different routes induce immunity in cancer patients. J Immunol 166: 4254-4259, 2001.
35. Caux C, Massacrier C, Vanbervliet B, Dubois B, Durand I, Cella M, Lanzavecchia A and Banchereau J: CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to granulocyte-macrophage colony-stimulating factor plus tumor necrosis factor alpha: II. Functional analysis. Blood 90: 1458-1470, 1997.
36. Liu YJ, Kanzler H, Soumelis V and Gilliet M: Dendritic cell lineage, plasticity and cross-regulation. Nat Immunol 2: 585-589, 2001.
37. Lanzavecchia A and Sallusto F: The instructive role of dendritic cells on T cell responses: lineages, plasticity and kinetics. Curr Opin Immunol 13: 291-298, 2001.
38. Langenkamp A, Messi M, Lanzavecchia A and Sallusto F: Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells. Nat Immunol 1: 311-316, 2000.
39. Moser M and Murphy KM: Dendritic cell regulation of TH1-TH2 development. Nat Immunol 1: 199-205, 2000.
40. Pulendran B, Palucka K and Banchereau J: Sensing pathogens and tuning immune responses. Science 293: 253-256, 2001.
41. Young JW: Dendritic cells: expansion and differentiation with hematopoietic growth factors. Curr Opin Hematol 6: 135-144, 1999.
42. Mortarini R, Anichini A, Di Nicola M, Siena S, Bregni M, Belli F, Molla A, Gianni AM and Parmiani G: Autologous dendritic cells derived from CD34+ progenitors and from monocytes are not functionally equivalent antigen-presenting cells in the induction of melan-A/Mart-1(27-35)-specific CTLs from peripheral blood lymphocytes of melanoma patients with low frequency of CTL precursors. Cancer Res 57: 5534-5541, 1997.
43. Ferlazzo G, Wesa A, Wei WZ and Galy A: Dendritic cells generated either from CD34+ progenitor cells or from monocytes differ in their ability to activate antigen-specific CD8+ T cells. J Immunol 163: 3597-3604, 1999.
44. Chen B, Stiff P, Sloan G, Kash J, Manjunath R, Pathasarathy M, Oldenburg D, Foreman KE and Nickoloff BJ: Replicative response, immunophenotype, and functional activity of monocyte-derived versus CD34(+)-derived dendritic cells following exposure to various expansion and maturational stimuli. Clin Immunol 98: 280-292, 2001.
45. Herbst B, Kohler G, Mackensen A, Veelken H, Mertelsmann R and Lindemann A: CD34+ peripheral blood progenitor cell and monocyte derived dendritic cells: a comparative analysis. Br J Haematol 99: 490-499, 1997.
46. Jonuleit H, Schmitt E, Schuler G, Knop J and Enk AH: Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 192: 1213-1222, 2000.
47. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C and Bhardwaj N: Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 193: 233-238, 2001.
48. Morse MA, Coleman RE, Akabani G, Niehaus N, Coleman D and Lyerly HK: Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res 59: 56-58, 1999.
49. Santin AD, Hermonat PL, Ravaggi A, Chiriva-Internati M, Zhan D, Pecorelli S, Parham GP and Cannon MJ: Induction of human papillomavirus-specific CD4(+) and CD8(+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer. J Virol 73: 5402-5410, 1999.
50. Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L and Brugger W: Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 96: 3102-3108, 2000.
51. Chakraborty NG, Sporn JR, Tortora AF, Kurtzman SH, Yamase H, Ergin MT and Mukherji B: Immunization with a tumor-cell-lysate-loaded autologous-antigen-presenting-cell-based vaccine in melanoma. Cancer Immunol Immunother 47: 58-64, 1998.
52. Höltl L, Rieser C, Papesh C, Ramoner R, Herold M, Klocker H, Radmayr C, Stenzl A, Bartsch G and Thurnher M: Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J Urol 161: 777-782, 1999.
53. Geiger J, Hutchinson R, Hohenkirk L, McKenna E, Chang A and Mule J: Treatment of solid tumours in children with tumour-lysate-pulsed dendritic cells. Lancet 356: 1163-1165, 2000.
54. Hernando JJ, Park TW, Kubler K, Offergeld R, Schlebusch H and Bauknecht T: Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: clinical and immunological evaluation of a phase I trial. Cancer Immunol Immunother 51: 45-52, 2002.
55. Gong J, Nikrui N, Chen D, Koido S, Wu Z, Tanaka Y, Cannistra S, Avigan D and Kufe D: Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. J Immunol 165: 1705-1711, 2000.
56. Boczkowski D, Nair SK, Nam JH, Lyerly HK and Gilboa E: Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res 60: 1028-1034, 2000.
57. Heiser A, Coleman D, Dannull J, Yancey D, Maurice MA, Lallas CD, Dahm P, Niedzwiecki D, Gilboa E and Vieweg J: Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 109: 409-417, 2002.
58. Heiser A, Dahm P, Yancey DR, Maurice MA, Boczkowski D, Nair SK, Gilboa E and Vieweg J: Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro. J Immunol 164: 5508-5514, 2000.
59. Heiser A, Maurice MA, Yancey DR, Coleman DM, Dahm P and Vieweg J: Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T-cell responses against antigens expressed by primary and metastatic tumors. Cancer Res 61: 3388-3393, 2001.
60. Heiser A, Maurice MA, Yancey DR, Wu NZ, Dahm P, Pruitt SK, Boczkowski D, Nair SK, Ballo MS, Gilboa E and Vieweg J: Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA. J Immunol 166: 2953-2960, 2001.
61. Thornburg C, Boczkowski D, Gilboa E and Nair SK: Induction of cytotoxic T lymphocytes with dendritic cells transfected with human papillomavirus E6 and E7 RNA: implications for cervical cancer immunotherapy. J Immunother 23: 412-418, 2000.
62. Slansky JE, Rattis FM, Boyd LF, Fahmy T, Jaffee EM, Schneck JP, Margulies DH and Pardoll DM: Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity 13: 529-538, 2000.
63. Thurner B, Haendle I, Roder C, Dieckmann D, Keikavoussi P, Jonuleit H, Bender A, Maczek C, Schreiner D, von den Driesch P, Brocker EB, Steinman RM, Enk A, Kampgen E and Schuler G: Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 190: 1669-1678, 1999.
64. Peoples GE, Goedegebuure PS, Smith R, Linehan DC, Yoshino I and Eberlein TJ: Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci USA 92: 432-436, 1995.
65. Brossart P, Heinrich KS, Stuhler G, Behnke L, Reichardt VL, Stevanovic S, Muhm A, Rammensee HG, Kanz L and Brugger W: Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood 93: 4309-4317, 1999.
66. Peoples GE, Anderson BW, Lee TV, Murray JL, Kudelka AP, Wharton JT and Ioannides CG: Vaccine implications of folate binding protein, a novel cytotoxic T lymphocyte-recognized antigen system in epithelial cancers. Clin Cancer Res 5: 4214-4223, 1999.
67. Whitehouse C and Solomon E: Current status of the molecular characterization of the ovarian cancer antigen CA125 and implications for its use in clinical screening. Gynecol Oncol 88: S152-157, 2003.
68. Carr JA, Havstad S, Zarbo RJ, Divine G, Mackowiak P and Velanovich V: The association of HER-2/neu amplification with breast cancer recurrence. Arch Surg 135: 1469-1474, 2000.
69. Disis ML, Pupa SM, Gralow JR, Dittadi R, Menard S and Cheever MA: High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol 15: 3363-3367, 1997.
70. Disis ML, Knutson KL, Schiffman K, Rinn K and McNeel DG: Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer. Breast Cancer Res Treat 62: 245-252, 2000.
71. Disis ML, Grabstein KH, Sleath PR and Cheever MA: Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin Cancer Res 5: 1289-1297, 1999.
72. Rongcun Y, Salazar-Onfray F, Charo J, Malmberg KJ, Evrin K, Maes H, Kono K, Hising C, Petersson M, Larsson O, Lan L, Appella E, Sette A, Celis E and Kiessling R: Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. J Immunol 163: 1037-1044, 1999.
73. Murray JL, Gillogly ME, Przepiorka D, Brewer H, Ibrahim NK, Booser DJ, Hortobagyi GN, Kudelka AP, Grabstein KH, Cheever MA and Ioannides CG: Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer. Clin Cancer Res 8: 3407-3418, 2002.
74. Zaks TZ and Rosenberg SA: Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors. Cancer Res 58: 4902-4908, 1998.
75. Ossendorp F, Toes RE, Offringa R, van der Burg SH and Melief CJ: Importance of CD4(+) T helper cell responses in tumor immunity. Immunol Lett 74: 75-79, 2000.
76. Knutson KL, Schiffman K and Disis ML: Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest 107: 477-484, 2001.
77. Taylor-Papadimitriou J, Burchell J, Miles DW and Dalziel M: MUC1 and cancer. Biochim Biophys Acta 1455: 301-313, 1999.
78. Syrigos KN, Karayiannakis AJ and Zbar A: Mucins as immunogenic targets in cancer. Anticancer Res 19: 5239-5244, 1999.
79. Snijdewint FG, von Mensdorff-Pouilly S, Karuntu-Wanamarta AH, Verstraeten AA, van Zanten-Przybysz I, Hummel P, Nijman HW, Kenemans P and Hilgers J: Cellular and humoral immune responses to MUC1 mucin and tandem-repeat peptides in ovarian cancer patients and controls. Cancer Immunol Immunother 48: 47-55, 1999.
80. Wright SE, Kilinski L, Talib S, Lowe KE, Burnside JS, Wu JY, Dolby N, Dombrowski KE, Lebkowski JS and Philip R: Cytotoxic T lymphocytes from humans with adenocarcinomas stimulated by native MUC1 mucin and a mucin peptide mutated at a glycosylation site. J Immunother 23: 2-10, 2000.
81. Musselli C, Ragupathi G, Gilewski T, Panageas KS, Spinat Y and Livingston PO: Reevaluation of the cellular immune response in breast cancer patients vaccinated with MUC1. Int J Cancer 97: 660-667, 2002.
82. Scholl SM, Balloul JM, Le Goc G, Bizouarne N, Schatz C, Kieny MP, von Mensdorff-Pouilly S, Vincent-Salomon A, Deneux L, Tartour E, Fridman W, Pouillart P and Acres B: Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer. J Immunother 23: 570-580, 2000.
83. Maruyama K, Akiyama Y, Nara-Ashizawa N, Hojo T, Cheng JY, Mizuguchi H, Hayakawa T and Yamaguchi K: Adenovirus-mediated MUC1 gene transduction into human blood-derived dendritic cells. J Immunother 24: 345-353, 2001.
84. Pecher G, Haring A, Kaiser L and Thiel E: Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a phase I/II clinical trial. Cancer Immunol Immunother 51: 669-673, 2002.
85. Trevor KT, Hersh EM, Brailey J, Balloul JM and Acres B: Transduction of human dendritic cells with a recombinant modified vaccinia Ankara virus encoding MUC1 and IL-2. Cancer Immunol Immunother 50: 397-407, 2001.
86. Vanderlugt CL and Miller SD: Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol 2: 85-95, 2002.
87. Bagnoli M, Canevari S, Figini M, Mezzanzanica D, Raspagliesi F, Tomassetti A and Miotti S: A step further in understanding the biology of the folate receptor in ovarian carcinoma. Gynecol Oncol 88: S140-144, 2003.
88. Kim DK, Lee TV, Castilleja A, Anderson BW, Peoples GE, Kudelka AP, Murray JL, Sittisomwong T, Wharton JT, Kim JW and Ioannides CG: Folate binding protein peptide 191-199 presented on dendritic cells can stimulate CTL from ovarian and breast cancer patients. Anticancer Res 19: 2907-2916, 1999.
89. zur Hausen H: Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2: 342-350, 2002.
90. Seedorf K, Oltersdorf T, Krammer G and Rowekamp W: Identification of early proteins of the human papilloma viruses type 16 (HPV 16) and type 18 (HPV 18) in cervical carcinoma cells. Embo J 6: 139-144, 1987.
91. von Knebel Doeberitz M, Bauknecht T, Bartsch D and zur Hausen H: Influence of chromosomal integration on glucocorticoid-regulated transcription of growth-stimulating papillomavirus genes E6 and E7 in cervical carcinoma cells. Proc Natl Acad Sci USA 88: 1411-1415, 1991.
92. Ressing ME, van Driel WJ, Celis E, Sette A, Brandt MP, Hartman M, Anholts JD, Schreuder GM, ter Harmsel WB, Fleuren GJ, Trimbos BJ, Kast WM and Melief CJ: Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A *0201-restricted E7-encoded epitope. Cancer Res 56: 582-588, 1996.
93. Evans EM, Man S, Evans AS and Borysiewicz LK: Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T-lymphocytes. Cancer Res 57: 2943-2950, 1997.
94. Steller MA, Gurski KJ, Murakami M, Daniel RW, Shah KV, Celis E, Sette A, Trimble EL, Park RC and Marincola FM: Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7. Clin Cancer Res 4: 2103-2109, 1998.
95. van Driel WJ, Ressing ME, Kenter GG, Brandt RM, Krul EJ, van Rossum AB, Schuuring E, Offringa R, Bauknecht T, Tamm-Hermelink A, van Dam PA, Fleuren GJ, Kast WM, Melief CJ and Trimbos JB: Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur J Cancer 35: 946-952, 1999.
96. Ressing ME, van Driel WJ, Brandt RM, Kenter GG, de Jong JH, Bauknecht T, Fleuren GJ, Hoogerhout P, Offringa R, Sette A, Celis E, Grey H, Trimbos BJ, Kast WM and Melief CJ: Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. J Immunother 23: 255-266, 2000.
97. Lanzavecchia A: Immunology. Licence to kill. Nature 393: 413-414, 1998.
98. Muderspach L, Wilczynski S, Roman L, Bade L, Felix J, Small LA, Kast WM, Fascio G, Marty V and Weber J: A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res 6: 3406-3416, 2000.
99. Zwaveling S, Ferreira Mota SC, Nouta J, Johnson M, Lipford GB, Offringa R, van der Burg SH and Melief CJ: Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol 169: 350-358, 2002.
100. Murakami M, Gurski KJ, Marincola FM, Ackland J and Steller MA: Induction of specific CD8+ T-lymphocyte responses using a human papillomavirus-16 E6/E7 fusion protein and autologous dendritic cells. Cancer Res 59: 1184-1187, 1999.
101. Santin AD, Bellone S, Gokden M, Cannon MJ and Parham GP: Vaccination with HPV-18 E7-pulsed dendritic cells in a patient with metastatic cervical cancer. N Engl J Med 346: 1752-1753, 2002.
102. Kaufmann AM, Nonn M, Ferrara A, Dürst M and Schneider A: Dendritic cells (DC) pulsed with recombinant human papillomavirus (HPV) 16 or 18 E7-protein induce specific CD4+ and CD8+ T lymphocytes in healthy individuals and cervical cancer patients. 7th International Symposium on Dendritic Cells. Bamberg, Germany, September 19-24, 2002.